, Russian Federation
, Russian Federation
GRNTI 76.35 Прочие отрасли медицины и здравоохранения
The article introduces ethical, clinical and scientific aspects of a medicinal drugs research, as well as particularities of conducting of clinical researches on a multiple sclerosis. The article presents major regulatory document on conduction of clinical researches of medicines in the Russian Federation.
clinical researches of medicines, multiple sclerosis, ethical aspects
1. Nacional'nyy standart RF «Nadlezhaschaya klinicheskaya praktika» GOST R 52379-2005.
2. Emanuel E.J., Wendler D., Grady C. What makes clinical research ethical? JAMA 2000; 283: 2701-2711.
3. http://acto-russia.org, 10 iyulya 2018. Informacionno-analiticheskiy byulleten' № 15, I polugodie 2017 g., Informacionno-analiticheskiy byulleten' № 16, itogi 2017 g.; Informacionno-analiticheskiy byulleten' № 17, I polugodie 2018 g.
4. Organizacionnye aspekty provedeniya klinicheskih issledovaniy. – M.: OOO Gruppa «Remedium», 2017. – 128 s.
5. https//ClinicalTrials.gov, 6 iyulya 2018.
6. Rasseyannyy skleroz (pod redakciey Guseva E.I., Zavalishina I.A., Boyko A.N.) M.: Real Taym, 2011. – 528 s.
7. Stolyarov I.D., Petrov A.M., Votinceva M.V. Atrofiya golovnogo mozga i effektivnost' preparatov patogeneticheskoy terapii pri rasseyannom skleroze. – Nervnye bolezni. – 2017. – № 4. – S. 10 –17.
8. Kappos L., Boyko A.N. Oral disease modifying therapy of multiple sclerosis: the current view. SS Korsakov Journal of Neurology and Psychiatry 2014; 114 (2-2):63-71.
9. Boster A.L., Ford C.C., Neudorfer O., Gilgun-Sherki Y. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. Expert Review Neurother. 2015; 15(6):575-86. Doi: 10.1586/14737175.2015.1040768.
10. Stolyarov I.D., Petrov A.M., Ivashkova E.V., Votinceva M.V., Nikiforova I.G. Innovacionnyy mehanizm deystviya preparata fingolimod pri rasseyannom skleroze. – Russkiy medicinskiy zhurnal (Klinicheskaya farmakologiya). – T. 19, №29, 2011. – S. 1812-1815.
11. Coles A.J., Fox E., Vladic A., Gazda S.K., Brinar V., Selmaj K.W., Skoromets A., Stolyarov I., Bass A., Sullivan H., Margolin D.H., Lake S.L., Moran S.., Palmer J, Smith M.S., Compston D.A. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012 Apr 3; 78(14):1069-78.
12. Alifirova V.M., Boyko A.N., Vlasov Ya.V., Davydovskaya M.V., Zaharova M.N., Malkova N.A., Popova E.V., Siverceva S.A., Spirin N.N., Hachanova N.V., Shmidt T.E. Klinicheskie rekomendacii po primeneniyu preparata dimetilfumarat pri remittiruyusche-recidiviruyuschem rasseyannom skleroze. – Zhurnal nevrologii i psihiatrii im. C.C.Korsakova. – 2017; 117(1):97-102.
13. Confavreux C., O’Connor P., Comi G. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(3):247-256.
14. Hachanova N.V., Bahtiyarova K.Z., Boyko A.N., Vlasov Ya.V Davydovskaya M.V., Evdoshenko E.P., Zaharova M.N., Malkova N.A., Siverceva S.A., Spirin N.N., Stolyarov I.D., Shmidt T.E., Habirov F.A. Obespechenie bezopasnosti terapii alemtuzumabom – odna iz glavnyh sostavlyayuschih farmakonadzora. – Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. – 2018; 118 (8-2): 82-87.
